ArticlePloS one2026
A multimodal ConvNeXt-Tiny deep learning model for simultaneous prediction of IDH mutation and Ki-67 expression in gliomas.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo construct and validate a multi-task deep learning model based on ConvNeXt-Tiny for synchronous prediction of isocitrate dehydrogenase (IDH) mutation status and Ki-67 expression level in gliomas. MATERIALS AND
methodsThis retrospective multicenter study included adult patients with diffuse glioma from two hospitals, which served as the training set and the independent validation set, respectively. All patients underwent multimodal MRI examinations within 4 weeks before surgery, including T2-weighted imaging (T2WI), T2-fluid attenuated inversion recovery (T2-FLAIR), contrast-enhanced T1-weighted imaging (T1CE), and three-dimensional arterial spin labeling imaging (ASL). MRI data were uniformly preprocessed to extract traditional radiomics features, and a dual-task deep learning model based on ConvNeXt-Tiny was constructed. Clinical characteristics, radiomics features, and deep learning features were multimodally fused to establish the multimodal model and were compared with other prediction models. Model performance and clinical utility were evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis, and the net reclassification index (NRI). SHapley additive explanations (SHAP) analysis and gradient-weighted class activation mapping (Grad-CAM) were applied for visual interpretation of model decisions.
resultsThe multimodal model demonstrated the best diagnostic performance for both IDH mutation status and Ki-67 expression level prediction. For IDH prediction, the multimodal model achieved AUCs of 0.901 and 0.883 in the training set and test set, respectively, while for Ki-67 prediction, the area under the curves (AUCs) reached 0.939 and 0.924. NRI analysis further confirmed that the multimodal model significantly improved case reclassification in both tasks. Calibration curves and the Hosmer-Lemeshow test indicated good model fit, and decision curve analysis showed a higher net clinical benefit. SHAP analysis revealed that model predictions mainly relied on deep learning features, particularly those derived from T1CE, ADC, and cerebral blood flow (CBF) images, whereas radiomics features and clinical variables contributed less. Grad-CAM visualizations demonstrated that the model primarily focused on tumor-related regions.
conclusionThis study developed a ConvNeXt-Tiny-based multi-task model that enables preoperative synchronous prediction of IDH mutation and Ki-67 status in adult diffuse glioma and exhibits robust performance superior to single-task and traditional models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.